FOSUN INTERNATIONAL LTD

Fosun International’s new partnership with Virax Biolabs expands its diagnostics reach across six Southeast Asian markets, boosting its portfolio and revenue potential.

Fosun International’s 2025 results show a 54.7% overseas revenue share, a push into pharma & healthcare, and a 10 billion‑RMB profit target as it streamlines its portfolio.

Fosun International’s latest 2025 stock snapshot shows a resilient yet volatile industrial conglomerate—market cap HK$40 billion, P/E‑negative, 52‑week range 3.74‑6.81 HKD, still driving global health, wealth and happiness services.

Fosun International Ltd is emerging as a leader in sustainable development and strategic partnerships, with ambitious climate goals and a new partnership with Nanyang Commercial Bank driving its growth and innovation.